hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases

Sponsor
Xuanwu Hospital, Beijing
Study ID
NCT06607900
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • hUC-MSC-sEV-001 nasal drops — DRUG
    hUC-MSC-sEV-001 nasal drops

Study Details

To evaluate the safety and preliminary efficacy of human umbilical cord mesenchymal stem cell-derived small extracellular vesicles hUC-MSC-sEV-001 nasal drops in multiple neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, multiple system atrophy, Lewy body dementia, frontotemporal dementia, and amyotrophic lateral sclerosis.

Key Dates

First listed
Sep 23, 2024
Start date
Jul 1, 2025
Status verified
Jul 2025
Primary completion
Aug 31, 2027
Completion
Aug 31, 2028

Study Design

Enrollment
120 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: hUC-MSC-sEV-001 group
    hUC-MSC-sEV-001 nasal drops treatment

Primary Outcome Measure

Alzheimer's disease: Change in Alzheimer's disease assessment scale-cognitive section（ADAS-cog） [ Time Frame: 12 months ]

Central Contacts

Find similar trials

Nationwide
Alzheimer's disease trialsParkinson's disease trialsNeurology trialsDementia care trialsBrain disorders trialsGeriatrics trials

Related Studies